retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 for Obesity: Weight-Loss Data Beyond GLP-1: Retatrutide's triple-agonist mechanism
Description
Morse, GLP-1s are definitely not a one-trick pony. What is GLP-1, and how do GLP-1 receptor agonists combat obesity and diabetes
The figure below is from Pratley2018
V., Hertz, C
These mechanisms help explain why GLP-1s appear to trigger a significant 12% to 18% weight loss on average
The peptide sequences were recovered directly from sorted cells by PCR and cloned into lentiviral vectors to construct libraries for next round selection
The ADJUNCT ONE trial found that symptomatic hypoglycemia had a dose-related effect with a rate ratio between 1.27 and 1.31 on doses of 1.2 and 1.8 mg of liraglutide, respectively
